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Abstract
In the present study, we sought to define the importance of serum IgA (sIgA)-mediated immunity in HIV-2 infection. Serum samples
from a total of 29 HIV-2-infected patients from Guinea-Bissau (n  20) and Portugal (n  9) were studied. Samples from seronegative
individuals were used as controls. Antibody reactivity to native and recombinant envelope glycoproteins as well as peptides representing
various regions of the envelope glycoproteins was investigated. Furthermore, the capacity of purified IgA to neutralize the HIV-2SBL6669
strain was tested. All serum samples showed IgA reactivity against whole HIV-2 antigen. Twenty-eight out of 29 IgA samples (96%) reacted
with native HIV-2 gp125, 26/29 (90%) with recombinant gp105, and 29/29 (100%) with recombinant gp36. When using peptides, the most
prominent IgA reactivity was seen against the peptide representing aa 644–658 of the transmembranous protein gp36, to which 72% of the
sera reacted. Purified sIgA antibodies showed neutralizing effects against HIV-2SBL6669 in 17/29 cases (59%). This work decribes the
HIV-2-specific sIgA antigenic response. Moreover, our findings show, for the first time, that sIgA may play a role in the in vitro
neutralization of HIV-2.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
HIV-2, the second type of lentivirus discovered to cause
immunodeficiency in humans, was first isolated from a
West African patient (Albert et al., 1987; Clavel et al., 1986;
Kanki et al., 1987). HIV-2 is confined mainly to West
Africa where the highest prevalence rates have been re-
ported from Guinea-Bissau. Fairly high numbers have also
been detected in Portugal and in India.
The envelope proteins play, as with other enveloped
viruses, an important role in the interaction with the recep-
tor, in fusion, induction of cytopathic effect, and develop-
ment of humoral and cellular immune responses. The two
glycoproteins are known to be highly antigenic and immu-
nogenic. HIV-2 infections, like HIV-1 infections, result in
the production of neutralizing antibodies predominantly di-
rected against regions in the envelope glycoprotein (Ranki
et al., 1987; Weiss et al., 1985) and there is also in vitro
evidence of HIV-2-specific antibodies with capacity to neu-
tralize HIV-1 (Bo¨ttiger et al., 1989, 1990; Robert-Guroff et
al., 1992; Weiss et al., 1988). The primary neutralizing
anti-HIV-2 immunoglobulin G (IgG) antibody response is
strain specific and directed against the third variable region
(V3) (Bjo¨rling et al., 1991, 1994; Matsushita et al., 1995;
McKnight et al., 1996; Mo¨rner et al., 1999). Also other
regions within HIV-2 gp125 have epitopes important for
IgG binding (Bjo¨rling et al., 1991; Skott et al., 1999).
At a later phase a more broadly reactive virus-neutraliz-
ing activity in the sera of HIV-1-infected individuals can be
found. Antibodies responsible for HIV-2-neutralizing activ-
ity have been characterized to predominantly identify dis-
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continuous sites and of particular importance in this context
may be the discontinuous structures responsible for the CD4
binding to the native gp125 (for review, see Bjo¨rling et al.,
1996, 1999). All these studies have been focused on the
biological activity mediated by HIV-2-specific IgG.
The demonstration of HIV-1-specific IgA directed
against envelope (Env) glycoproteins suggests a potential
role for IgA in viral neutralization, as functional IgA serves
in a defensive capacity against other human viral pathogens
(Dimmock, 1993). Kozlowski and co-workers (1994)
showed an increased production of HIV-1-specific poly-
meric serum IgA (sIgA) due to the rise of both subclasses
IgA1 and IgA2 during early HIV-1 infection. Serum IgA1
(sIgA1) antibodies were directed predominantly against the
envelope glycoproteins, and for patients with AIDS and
symptomatic HIV-1 infection a declining titer of sIgA an-
tibodies against these antigens could be seen. We and other
groups have earlier shown IgA-mediated neutralization of
HIV-1 (Devito et al., 2000a, b; Kozlowski et al., 1994; Skott
et al., submitted) and a role for IgA-mediated HIV-1 neu-
tralization in vivo has also been suggested (Burrer et al.,
2001). We have also quantitatively compared the biological
function of HIV-1-specific serum IgA (sIgA)/secretory IgA
(S-IgA) versus immunoglobulin G (IgG) antibodies per mil-
ligram both against laboratory-adapted virus and primary
isolates and found that IgA antibodies seem to be more
effective in neutralizing HIV-1 as opposed to IgG (Skott et
al., submitted). We could also correlate a strong sIgA-
mediated HIV-1-neutralizing activity with defined epitope
specificity with preference for the V4 region of gp120
(Skott et al., 1999), in contrast to sera derived from highly
exposed HIV-1 individuals with preference for an epitope,
LQAR, within the coil-coiled pocket in the aminoterminal
part of gp 41 (Pastori et al., 2000).
This is the first study describing an HIV-2-specific hu-
moral sIgA antigenic and neutralizing response, and further-
more we show the epitope specificity of HIV-2-specific
sIgA derived from HIV-2 serum.
Results
Purification of IgA1
IgA1 could be purified from all serum samples with an
average purification efficiency of 85%, with purity and
possible residual contaminating IgG evaluated by Com-
massie-stained electrophoresis gels (Fig. 1). No high-mass
molecular weight proteins or residual IgG in the serum
samples could be detected. To confirm these results an
ELISA was performed using the same samples to determine
that the amount of residual IgG did not exceed 0.1 g/ml. A
similar procedure was performed for purified IgG to elim-
inate IgA contamination. OD values ranged from 0.14 to
0.169 for purified IgG samples and from 0.051 to 0.210 for
purified IgA samples, respectively.
Quantification of total sIgA and IgG
sIgA could be detected in all serum samples at individual
values of 0.3–7.1 mg/ml. The values of the control group
ranged from 0.1 to 4.2 mg/ml. The mean values of total
sIgA derived from HIV-2 antibody-positive patients did not
differ significantly compared to the control group.
Total serum IgG concentrations ranged between 0.2 and
7.5 mg/ml. The values for the control group ranged between
0.3 and 5.5 mg/ml. Total serum IgG levels in the African
controls were not done.
Antibody reactivity against whole HIV-2 antigen, native
and recombinant envelope proteins of HIV-2
All serum samples 29/29 (100%) showed IgA reactivity
against the whole HIV-2 antigen. For native gp125 a similar
pattern could be seen. Twenty-eight out of 29 samples
(96%) were positive in IgA ELISA, for rgp105 26/29 (90%)
and rgp36 29/29 (100%), respectively. None of the controls
showed sIgA reactivity to whole HIV-2 antigen, native
gp125, gp105, or gp36 (Table 1).
All serum samples showed IgG reactivity against whole
HIV-2 antigen, native gp125, and rgp105 in ELISA. For
rgp36, 25 out of 29 sera showed reactivity. None of the
controls showed any seroreactivity to either protein (data
not shown).
Quantification of IgA in relation to ELISA reactivity
against HIV-2 proteins
To compare reactivity between the HIV-2 serum samples
used in ELISA against native gp125, rgp105, and rgp36, the
IgA OD values were also expressed as OD value/mg total
purified IgA to the different proteins (Fig. 2). All of the
proteins were coated onto the plate in the same concentra-
tion (0.1 g/well), and when comparing between the dif-
ferent proteins used, all sera displayed the highest reactivity
in OD value/mg IgA against rgp36.
Fig. 1. SDS-PAGE separated and Coomassie blue-stained purified immu-
noglobulin G (IgG) and immunoglobulin A (IgA) serum fractions from two
HIV-2-positive patients. Lanes B and D represent purified IgG from serum
and lanes C and E purified IgA from serum. The migration of molecular
weight standards is indicated in kDa to the left (A).
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IgA antibody reactivity in serum to synthetic peptides
corresponding to the envelope proteins of HIV-2
The external glycoprotein of the envelope of HIV-2 was
mimicked by six different peptides corresponding to the
second variable region (V2, aa 160–186), two different
parts of the third variable region (V3, aa 283–297 and aa
311–337), and the fourth variable region (V4, aa 399–419)
(Table 1).
The peptide representing the V2 region was recognized
by IgA antibodies in 4 out of 29 patients (14%), and no
serum IgA reactivity could be seen against the peptide
representing the V2/C2 region (189–205). The IgA serore-
activity to the peptides representing the V3-loop was stron-
gest to the peptide corresponding to the aminoterminal part
of the loop (aa 283–297), with 8/29 (28%) positive samples,
compared to the peptides mimicking a more C-terminal part
of the V3 region (aa 311–337) which showed lower reac-
tivity, 3/29 (10%) and 7/29 (24%), respectively (Table 1).
Only 2 out of 29 samples (7%) recognized the peptide
representing the V4 region aa 399–419 (Table 1). The
transmembraneous protein, gp36, was represented by four
Table 1
Amino acid sequences of synthetic peptides corresponding to selected linear sites in the envelope glycoproteins of HIV-2
Peptide Residues Region Amino acid sequence Serum IgA reactivity (%)
S1–2 160–186/ROD V2 CQFNMTGLERDKKKQYNETWYSKDVVCa 14
S1–19 189–205/ROD V2/C2 CETNNSTNQTQCYMNHC —c
S11–11 283–297/ROD V3 SGLVFHSHYQPINKR 28
A43–29 311–330/ISY V3 SGRRFHSQKIINKKPRQAWC 10
A43–36 318–337/ISY V3 QKIINKKPRQAWCRFKGEWR 24
S1–18 399–419/ROD V4 CNMTWFLNWIENKTHRNYAPC 7
S12–37 582–603/ISY gp36 RLNSWGCAFRQVCHTTVPWVND 38
A43–9 615–634/ISY gp36 WQEWEHKIRFLEANISESLE(C)b 45
A43–10 634–648/ISY gp36 EQAQIQQEKNMYELQ(C) 45
A43–12 644–658/ISY gp36 MYELQKLNSWDVFGN(C) 72




Reactivity mediated by IgA derived from a panel (n  29) of human anti-HIV-2 sera against whole viral lysate, native gp125, rgp105, rgp36, and peptides
are also shown.
a Amino acid sequences were derived from the published sequences of the HIV-2 ROD and the ISY molecular clone of the SBL6669 HIV-2 strain [33].
b (C), a C-terminal cysteine was added to the peptide to allow coupling to keyhole limpet hemocyanin.
c No IgA antibody reactivity was seen.
Fig. 2. Antibody reactivity in ELISA mediated by IgA derived from a panel (n  29) of human anti-HIV-2 sera against HIV-2 native gp125, rgp105, and
rgp36. All proteins were coated in a concentration of 0.1 g/well. OD values/mg Ig are expressed on the y axis and categories on the x axis represents the
individual sera.
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peptides corresponding to aa 582–603 and from aa 615 to aa
658. The peptide representing the amino terminal part of
gp36 was recognized by 11/29 (38%) serum IgA samples.
Peptides A43–9, 10, and 12 were recognized by 45, 45, and
72% of the sera, respectively. The most prominent IgA
activity could be seen against aa 644–658 (Table 1).
Neutralizing activity of individual serum samples against
HIV-2SBL6669
Purified sIgA antibodies showed a neutralizing effect
against HIV-2SBL6669 in 17/29 cases with titers between 40
and 80 (Fig. 3). The neutralizing activity mediated by sIgA
antibodies could not be correlated to the total amount of IgA
in serum. Furthermore, neither a high sIgA reactivity to
rgp36 nor a high gp125/gp105 reactivity (OD/mg) was
indicative of antibodies with virus-neutralizing capacity.
This was exemplified by samples 5, 24, and 28 that exhib-
ited high rgp36 reactivity and sample 14 that exhibited high
gp125 reactivity yet showed no detectable neutralizing ac-
tivity.
Neutralization mediated by purified IgG from serum
against HIV-2SBL6669 could be observed in 19 out of 29
cases with titers ranging from 20 to 80 (Fig. 3), with a
somewhat lower activity compared to the same samples of
purified IgA. Whole serum-mediated neutralization of HIV-
2SBL6669 could be confirmed in 20 out of 29 cases with titers
ranging from 40 to 160 (Fig. 3). Neutralizing activity was
observed both in sera derived from HIV-2-positive patients
from Guinea-Bissau and Portugal. No neutralizing activity
was detected in any of the control serum samples (whole
serum, purified sIgA or IgG).
Quantification of IgA in relation to neutralizing activity
To compensate for the variation in IgA and IgG concen-
tration and subsequently in the amount of IgA and IgG
obtained during purification, HIV-2-neutralizing IgA and
IgG titers were also expressed as neutralizing IgA (or IgG)
titer/mg total purified IgA (or IgG). When comparing Igs
per milligram, IgG was shown to be more potent than IgA
in neutralization. No correlation could be seen between the
amount of purified IgA or IgG and the neutralizing titer
against HIV-2SBL6669 (data not shown).
Discussion
Besides immune exclusion, additional roles for IgA have
been recognized, such as blocking of the adherence for viral
antigens to the epithelial cells and inhibition of virus as-
sembly, internal neutralization (Mazanec et al., 1993). Hu-
man serum IgA can initiate phagocytosis by Kuppfer cells
(liver cells) in vivo (probably are S-IgA too large to be
important) shown by phagocytosis of bacteria. This sug-
gests a second line of defense in mucosal immunity, by
eliminating invasive bacteria entering through the portal
circulation and thus preventing disease (van Egmond et al.,
2000).
IgA-mediated neutralization has been shown for many
viral pathogens. Among these are poliovirus, cytomegalo-
virus, type A influenza virus (Dimmock, 1993), Puumala
hanta virus (de Carvalho et al., 2000), rotaviruses (Green-
berg et al., 1988; Johansen and Svensson, 1994), and Ep-
stein Barr virus (Yao et al., 1991). We and other groups
Fig. 3. Neutralizing activity against the T-cell-line-adapted strain HIV-2SBL6669 mediated by whole serum in correlation to purified antibodies (IgA, black
bars; IgG, gray bars; and whole serum, white bars). Neutralization titer (NT) is defined by the last dilution resulting in a 80% reduction of infectivity of
the virus in peripheral blood mononuclear cells. NTs are expressed on the y axis and categories on the x axis represents the individual sera.
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have earlier shown this phenomenon also for HIV-1 (Devito
et al., 2000a, b; Moja et al., 2000; Skott et al., submitted).
In another study describing uninfected HIV-exposed in-
dividuals, Mazzoli and co-workers (1999) reported that the
sIgA protecting against infection recognized HIV epitopes
located at the transmembrane protein while the HIV-posi-
tive individuals recognized mainly gp120 and gp160.
In this study we analyzed the epitopes of HIV-2 recog-
nized by serum HIV-2-specific IgA in HIV-2-infected pa-
tients. The neutralizing activity mediated by sIgA antibod-
ies could not be correlated to the total amount of sIgA in
serum. A high sIgA reactivity to rgp36 or gp125/rgp105 was
not found to be directly indicative of neutralizing activity.
When using peptides corresponding to the external envelope
protein gp125, we could only find reactivity with purified
IgA in a small portion of the serum samples, at most 28% to
the V3 region. These results differ from earlier findings
reported by us for HIV-1 (Skott et al., 1999). However, we
could observe a strong sIgA-mediated neutralizing activity
in the same serum with distinct reactivity against peptides
corresponding to the central extramembrane region of gp36.
This is in line with earlier reported results for HIV-1-
specific IgA binding to two different neutralizing immuno-
dominant epitopes within the extramembrane portion of
gp41 (Muster et al., 1994; Pastori et al., 2000; Skott et al.,
1999; Vanini et al., 1993).
In three of our patient samples containing purified sIgA
or IgG antibodies we could see a strong neutralizing capac-
ity compared to a somewhat less efficient activity for ho-
mologous whole serum. Although this was a rare event in
the present study, this phenomenon has earlier been dis-
cussed in a study concerning influenza virus neutralization:
a low amount of purified IgG was more efficient in neutral-
ization as compared to whole serum, due to the axial rota-
tion and necessary mobility for the antibody to bind and
inhibit the virus (Dimmock, 1993).
In conclusion, we have reported, for the first time, that
human sIgA antibodies derived from whole serum in natural
HIV-2 infection have the capacity to neutralize HIV-2. Our
data in this study demonstrate, without excluding possible roles
of other Ig subclasses, that in addition to IgG, sIgA plays an
important role in the in vitro neutralization of HIV-2.
The identification of viral immunodominant epitopes im-
portant for protection via an IgA-mediated response against
HIV could be one tool for the development of new therapies
against HIV infection. Further studies will be required to
define the in vivo protective role of both sIgA and muco-
sally derived secretory IgA in HIV-2 infection.
Materials and methods
Serum samples
The study group consisted of 20 HIV-2 antibody-positive
sera derived from patients from a cohort in Guinea-Bissau
and 9 sera derived from HIV-2-positive patients from Por-
tugal. Furthermore, 12 HIV-2 seronegative sera derived
from the same cohort in Guinea-Bissau and 7 healthy sero-
negative samples derived from individuals living in Sweden
were included as controls.
Blood samples were drawn from the subjects, whole
blood was centrifuged at 1200 rpm, and serum was sepa-
rated and stored immediately at 20°C until analyzed. The
serum samples were inactivated at 56°C for 30 min before
use.
Peptide synthesis
Ten peptides representing previously known IgG-spe-
cific antigenic sites in the envelope proteins of HIV-2 were
synthesized as earlier described by Bjo¨rling and co-workers
(1991). The peptide amino acid sequences were derived
from the published sequences of HIV-2ISY and HIV-2ROD
(Table 1). All peptides were analyzed using high-perfor-
mance liquid chromatography (HPLC) to confirm their
grade of purity, exceeding 65% before use.
Whole HIV-2 antigen, native gp125, and recombinant
glycoproteins
As whole HIV-2 antigen, we used purified virions of
SBL6669 grown on U937:2 cells, kindly provided by Pro-
fessor G. Biberfeld, Swedish Institute for Infectious Disease
Control. Native gp125, derived from HIV-2SBL6669, was
purified by affinity chromatography using Galanthus nivalis
agglutinin (Gilljam, 1993). Native gp125 was kindly pro-
vided by the department of Virology at the Swedish Institute
of Infectious Disease Control. Recombinant gp105
(rgp105), derived from HIV-2ROD, was produced in bacu-
lovirus expression system. Recombinant gp105 and gp36
(rgp36) were commercially obtained from Intracel (London,
UK) and ViroGen Corp. (Watertown, MA), respectively.
Purification of IgA and IgG antibodies
IgA was purified from serum on Artocarpus integrifolia
agglutinin (jacalin). Briefly, 200 l of jacalin/agarose beads
(Vector, Burlingame, CA) was added to 20 l of serum
diluted 1:10 in RIPA buffer (2% v/v Triton X-100, 150 mM
NaCl, 600 mM KCl, 5 mM dinatrium EDTA, pH 7.8). The
mixture was incubated on an end-to-end rotator at room
temperature for 2 h. After binding, the mixture was centri-
fuged for 3 min (10,000g) and washed three times with
low-salt extraction buffer (LSEB, 2% v/v Triton X-100, 150
mM NaCl, 600 mM KCl, 5 mM disodium EDTA, 3 mM
PMSF, 1 g aprotinin/ml in 10 mM Tris-HCl, pH 7.8), and
then eluted overnight at 4°C with 50 l 200 mM methyl-
-D-galactopyranoside. The following day, the supernatant
was harvested after centrifugation for 3 min (3000g). An
equal volume of protein G-Sepharose (Pharmacia, Uppsala,
Sweden) was added and incubated on an end-to-end rotator
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for 2 h to exclude remaining IgG from the first purification
step. After centrifugation for 3 min (3000g), the supernatant
containing IgA was harvested. The protein G-Sepharose
was washed with start buffer (20 mM Na2HPO4, pH 7.0),
and IgG was eluted with elution buffer (0.1 M glycine-HCl,
pH 2.2) for 10 min, followed by centrifugation for 1 min
(13,000 rpm). After harvest the eluted IgG was immediately
adjusted to pH 7 using neutralization buffer (2.5 M Tris-
Base, pH 9.0).
SDS electrophoresis gels
Separating gel was performed by mixing 3.9 ml acryl-
amide 40%, 2.1 ml bis-acrylamide 2%, 3.1 ml Tris-HCl 1.5
M, (pH 8.8), and 2.0 ml ddH2O and polymerization ingre-
dients 56 l, 20% SDS, 75 l ammonium persulfate, and
10% 5.6 l Temed and polymerized for 1 h at room tem-
perature.
The stacking gel was done by mixing 0.5 ml acrylamide
20%, 265 l bis-acrylamide 2%, 25 l SDS 20%, 665 l
Tris-HCl 0.5 M (pH 6.8), and 3.5 ml ddH2O and polymer-
ized with 100 l ammonium persulfate, and 10%, 3.5 l
TEMED for 1 h. The gel was thereafter kept at 4°C until
use.
The purified IgA and IgG samples (5 l) were mixed
with 15 l of sample buffer in Eppendorf tubes and heated
to 100°C for 3 min; thereafter the samples were loaded (20
l) onto the gel. Five microliters molecular weight markers
were included in each run as reference (Amersham Labo-
ratories, Buckinghamshire, Great Britain). The electro-
phoresis procedure was performed with running buffer (Tris
15.0 g, SDS 5.0 g, glycine 72.0 g, dest H2O up to 1000 ml)
at 100 V for 45 min. The next step was to stain the gel into
a staining buffer (0.25 g of Coomassie brilliant blue R-250
in 90 ml of methanol:H2O (1:1 v/v) and 10 ml of glacetic
acid) for 4 h onto a slow rocking platform. Destaining of the
gel was done overnight onto a slow rocking platform with
destaining buffer containing methanol/acetic acid solution
(20% methanol and 10% acetic acid). Thereafter the gel was
read and then put onto a filter paper with a thin plastic layer
on top and dried overnight in a vacuum gel dryer.
Quantification of immunoglobulins
An ELISA was used for quantification of total and pu-
rified IgA and IgG, respectively, and also as a control for
residual sIgA and IgG together with SDS electrophoresis
gels. Human IgA (Jackson Laboratories, WestGrove, PA)
and IgG (Calbiochem, San Diego, CA) were used to gen-
erate standards. The OD values were analyzed using DS3-
1.46B software (DeltaSoft 3, Biometallic Inc) on a com-
puter to calculate the concentrations of IgA and IgG,
respectively.
Enzyme-linked immunosorbent assay (ELISA)
Peptide, whole HIV-2 antigen, native gp125, rgp36 and
gp105 ELISAs were performed as follows. Briefly, micro-
titer plates (Nunc, Denmark) were coated overnight at room
temperature with in-house-made peptides (1 g/well),
gp125 (0.1 g/well), gp105 (0.1 g/well, Intracel), rgp36
(0.1 g/well, Virogen), or whole HIV-2 antigen (0.1 g/
well), respectively, dissolved in 0.05 M carbonate buffer,
pH 9.6. The following day the plates were washed with
ELISA-washing buffer (0.05% Tween 20 in PBS) and
blocking was performed with 5% bovine serum albumin at
37°C for 2 h. After washing, serum was added at a 1:100
dilution and incubated for 1 h at 37°C. After another wash,
biotinylated goat anti-human IgA conjugate (Southern Bio-
technology, Birmingham, AL) diluted 1:10,000 in conjugate
buffer (20% goat serum, 20% fetal calf serum, 0.5% bovine
serum albumin, and 0.05% Tween 20), 100 l/well, was
added for 1 h at 37°C. After washing, streptavidin-HRP
(Southern Biotechnology) was added as a second conjugate
diluted 1:5000 with conjugate buffer for 1 h at 37°C. After
a final washing step, o-phenylenediamine dihydrochloride
(OPD)-substrate was added. The reaction was allowed to
continue for 30 min and was then stopped by adding 2.5 M
H2SO4. Optical density values were read at 490 nm.
Neutralization assay
For the neutralization assay, the HIV-2 strain SBL-6669
was used. Peripheral blood mononuclear cells (PBMC)
from two healthy donors were prestimulated with phytohe-
magglutinin (PHA) for 3 days and then used in a neutral-
ization assay as previously described (Bjo¨rling et al., 1993).
Briefly, diluted tissue culture supernatant of virus-infected
peripheral blood mononuclear cells (50 TCID50, 100 l)
was incubated for 1 h at 37°C with 100 l antibody dilution.
PBMC (1  105) in 50 l was added to the virus-antibody
reaction mixture and incubated overnight. All dilutions
were performed in RPMI 1640 medium (GIBCO, Life
Technologies Ltd. Paisly, Scotland) supplemented with
10% fetal calf serum, 3 mM glutamine, IL-2, and antibiot-
ics. This medium mixture was also used for cell culture
during the experiment. Medium change was performed at
Days 1 and 4. Seven days after infection, supernatants were
collected and analyzed by a capture ELISA (Thorstensson et
al., 1991). The neutralization titer was defined as the last
dilution step that showed an 80% reduction or more of
optical density at 490 nm in the culture supernatant com-
pared to the HIV antibody-negative serum. Titers equal to or
above 20 were considered to represent positive neutraliza-
tion and assays were repeated at least on two occasions. The
purified IgA samples were not concentrated after purifica-
tion. The purified samples used in the neutralization assay
constituted a 1/2.5 dilution since 20 l serum was used
initially and the final volume after elution was 50 l. The
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neutralization assay was performed in six steps at twofold
dilutions.
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